Submission declined on 15 July 2026 by Ca (talk). This draft contains medical, health, or psychological claims. Wikipedia requires a higher standard of sourcing for biomedical content. To ensure accuracy, content must be based on reliable secondary sources that reflect current knowledge. The draft should: have high-quality secondary sources: such as systematic reviews, meta-analyses, or medical textbooks from respected publishers; avoid primary sources: such as direct research papers, clinical trials, or news reports on early studies. Please add references that meet these criteria. If none exist, the subject is not yet suitable for Wikipedia. This draft appears to contain text generated by a large language model (such as ChatGPT). You cannot use LLMs to generate article content. LLM-generated pages with certain obvious signs of being machine generated may be deleted without notice. Instead, only summarize in your own words a range of independent, reliable, published sources that discuss the subject. See the advice page on large language models for more information. If you would like to continue working on the submission, click on the "Edit" tab at the top of the window. If you have not resolved the issues listed above, your draft will be declined again and potentially deleted. If you need extra help, please ask us a question at the AfC Help Desk or get live help from experienced editors. Please do not remove reviewer comments or this notice until the submission is accepted. Where to get help If you need help editing or submitting your draft, please ask us a question at the AfC Help Desk or get live help from experienced editors. These venues are only for help with editing and the submission process, not to get reviews. If you need feedback on your draft, or if the review is taking a lot of time, you can try asking for help on the talk page of a relevant WikiProject. Some WikiProjects are more active than others so a speedy reply is not guaranteed. How to improve a draft Wikipedia:Contributing to Wikipedia – a basic overview on how to edit Wikipedia. Help:Wikitext – how to use the markup Help:Referencing for beginners – how to include references Wikipedia:Article development – how to develop your article Wikipedia:Writing better articles – how to improve your article Wikipedia:Verifiability – make sure your article includes reliable third-party sources You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Add tags to your draft Editor resources Easy tools: Citation bot (help) | Advanced: Fix bare URLs Declined by Ca 26 days ago. Last edited by Citation bot 22 days ago. Reviewer: Inform author. Resubmit Please note that if the issues are not fixed, the draft will be declined again.

• Comment: Besides the AI issue, Choi 2024 and Pachler 2012 does not mention SAGX at all. Using those sources to present a claim about SAGX is a WP:SYNTH violation. Ca ^{talk to me!} 16:35, 15 July 2026 (UTC)

• Comment: In accordance with the Wikimedia Foundation's Terms of Use, I disclose that I have been paid by my employer for my contributions to this article. David gnbio (talk) 11:11, 30 June 2026 (UTC)

SAGX is a standardized botanical extract derived from the root of Salvia miltiorrhiza (danshen, 丹參), a perennial herb native to China and East Asia long used in traditional Chinese medicine. SAGX is developed by the South Korean biotechnology company Qrome and exclusively supplied by GN BioSolution Co., Ltd. It contains defined concentrations of three bioactive compounds — cryptotanshinone, tanshinone IIA, and salvianolic acid B — standardized within specified ranges to minimize batch-to-batch variation in biological activity.

SAGX has been granted individual recognition as a functional ingredient by the South Korean Ministry of Food and Drug Safety (MFDS) with the permitted claim "may help maintain prostate health." It is regulated as a health functional food ingredient in South Korea, not as a pharmaceutical drug. Two peer-reviewed randomized controlled trials evaluating SAGX in men with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) have been published in the SCIE-indexed journal Nutrients.^[1][2]

The three principal bioactive constituents of SAGX and their reported pharmacological activities are:

Component	Chemical class	Reported activity
Cryptotanshinone	Lipophilic abietane diterpenoid	Direct inhibition of 5-alpha reductase (5α-reductase), reducing conversion of testosterone to dihydrotestosterone (DHT); suppression of DHT-driven androgen receptor activation and prostatic cell proliferation
Tanshinone IIA	Lipophilic abietane diterpenoid	Antioxidant, anti-inflammatory (NF-κB pathway inhibition), cardioprotective
Salvianolic acid B	Hydrophilic phenolic acid	Antioxidant, anti-inflammatory, reported prostatic tissue protection

Standardization of all three components within fixed concentration ranges is intended to ensure consistent biological activity across production batches, distinguishing SAGX from non-standardized S. miltiorrhiza preparations.

South Korea's health functional food regulations distinguish between two categories of functional ingredient authorization:

• General recognition (일반인정형) applies to ingredients with sufficient accumulated international scientific evidence, available for use by any manufacturer (examples include red ginseng, vitamin C, and omega-3 fatty acids).
• Individual recognition (개별인정형) is granted to a specific applicant company's ingredient following independent submission and MFDS review of preclinical safety data, clinical efficacy data, and manufacturing specifications. The associated functional claim is exclusive to the recognized ingredient; other manufacturers wishing to make the same claim must independently complete the full review process with their own data.^[3]

SAGX holds individual recognition status, meaning the claim "may help maintain prostate health" is authorized specifically for the Qrome-developed SAGX ingredient.

The primary proposed mechanism of SAGX involves cryptotanshinone's inhibition of 5-alpha reductase (5α-reductase), the enzyme that converts testosterone to dihydrotestosterone (DHT) in prostatic tissue. DHT binds to androgen receptors with several-fold greater affinity than testosterone and drives prostatic cell proliferation; the progressive accumulation of this process is a central pathophysiological mechanism of benign prostatic hyperplasia (BPH). This pharmacological target is shared by the prescription 5α-reductase inhibitors finasteride and dutasteride.

Preclinical cell and animal studies demonstrated that cryptotanshinone directly inhibits 5α-reductase and reduces DHT-mediated prostatic cell proliferation.^[4]

Salvianolic acid B and tanshinone IIA are reported to inhibit the NF-κB signaling pathway, suppressing overproduction of pro-inflammatory cytokines including IL-6 and TNF-α, and reducing oxidative stress in prostatic tissue. Chronic low-grade prostatic inflammation is recognized as an independent risk factor for BPH progression, suggesting these components may complement the DHT-reduction mechanism of cryptotanshinone.

A 12-week randomized, double-blind, placebo-controlled trial enrolled 136 men with LUTS associated with BPH. Participants received SAGX or a matching placebo daily. The SAGX group demonstrated statistically significant improvements compared to placebo across all primary endpoints:

• International Prostate Symptom Score (IPSS) — a validated 0–35 point self-report scale assessing urinary symptom severity; the SAGX group showed significant score reduction (improvement)
• Maximum urinary flow rate (Qmax) — objective measure of voiding efficiency; significant increase in the SAGX group
• Nocturia — number of nighttime voiding episodes; significant reduction in the SAGX group
• International Index of Erectile Function (IIEF) — significant improvement in the SAGX group

No serious adverse events attributable to SAGX were reported. The study was published in Nutrients in 2025 (PMID 39796461).

A 12-week randomized, double-blind trial directly compared SAGX 400 mg against saw palmetto (Serenoa repens) 320 mg in 30 men with LUTS/BPH. Saw palmetto is among the most widely used botanical supplements for prostate health internationally; however, systematic reviews and meta-analyses have found it to be no more effective than placebo in improving urinary symptoms or reducing prostate size.^[5]

In this direct comparison, SAGX was statistically superior to saw palmetto on all measured endpoints:

• IPSS total score reduction: SAGX superior (p = 0.031)
• Storage symptom subscale (frequency, nocturia, urgency): SAGX showed approximately 7.7-fold greater improvement than saw palmetto (p = 0.003)
• Quality of life (QoL) score: SAGX superior (p = 0.035)
• IIEF score: SAGX superior (p = 0.005)
• Adverse events: mild and transient in both groups; incidence did not differ significantly between arms

The study was published in Nutrients in 2026 (PMID 42280395).

• Salvia miltiorrhiza
• Benign prostatic hyperplasia
• Lower urinary tract symptoms
• 5-alpha reductase inhibitor
• Saw palmetto
• Phytotherapy

Category:Dietary supplements Category:Herbal extracts Category:Prostate disorders Category:Salvia Category:South Korean products